Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r… Read More

Emerging in the landscape of obesity therapy, retatrutide represents a distinct approach. Unlike many existing medications, retatrutide works as a double agonist, simultaneously affecting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) receptors. This concurrent stimulation encourages various beneficial effe… Read More